ClinicalTrials.gg
CompletedNCT01644474ODYSSEY MONOUpdated Nov 6, 2015Results posted

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia

A Phase 3 interventional study of Alirocumab and Ezetimibe in Hypercholesterolemia, sponsored by Sanofi. Completed at 8 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-11-06.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
23rd of 43
103 · median 107
Started
2012
with 11 others
Phase 3
20 of 43
none open now
Registered
16th of 43
by date
Lead sponsor
28 of 43
Sanofi

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 23rd largest by enrollment, is one of 12 that started in 2012, is one of 20 in phase 3, and was the 16th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).

Primary Objective of the study:

To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab in comparison with ezetimibe after 24 weeks of treatment in participants with hypercholesterolemia.

Secondary Objectives:

  • To evaluate the effect of alirocumab in comparison with ezetimibe on LDL-C at other time points
  • To evaluate the effect of alirocumab on other lipid parameters
  • To evaluate the safety and tolerability of alirocumab
Read the detailed description

The maximum study duration was 34 weeks per participant, including a 24-week randomized treatment period.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with hypercholesterolemia

Exclusion criteria

Exclusion criteria:

  • Age \< 18 or legal age of adulthood, whichever was greater
  • LDL-C \< 100 mg/dL (\< 2.59 mmol/L) or > 190 mg/dL (> 4.9 mmol/L)
  • Fasting serum triglycerides (TG) > 400 mg/dL (> 4.52 mmol/L)
  • Known history of homozygous or heterozygous familial hypercholesterolemia

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
103 participants (actual)

Study arms

  • Active comparator
    Ezetimibe 10 mg

    Oral ezetimibe 10 mg capsule daily and subcutaneous (SC) placebo injection for alirocumab every 2 weeks (Q2W) for 24 weeks.

    Drug: Ezetimibe · Drug: Placebo (for Alirocumab)

  • Experimental
    Alirocumab 75/Up to 150 mg Q2W

    SC injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe daily for 24 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.

    Drug: Alirocumab · Drug: Placebo (for Ezetimibe)

Interventions

  • 1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.

    Also known as: SAR236553, REGN727

  • One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.

  • DrugPlacebo (for Alirocumab)

    1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self--injection or by another designated person using the autoinjector.

  • DrugPlacebo (for Ezetimibe)

    One capsule orally once daily at approximately the same time of the day with or without food..

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis

    Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 24

Secondary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  2. Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  3. Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  4. Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  5. Percent Change From Baseline in Apo B at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  6. Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  7. Percent Change From Baseline in Total-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  8. Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis

    Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model.

    Time frame: Up to Week 24

  9. Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

    Adjusted percentages at Week 24 from multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: Up to Week 24

  10. Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  11. Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  12. Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  13. Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  14. Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  15. Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  16. Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  17. Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

07

Results

Posted Nov 6, 2015
Limitations and caveats
Due to administrative error in the automated process (which was detected after database lock), planned dose up-titration criteria for LDL-C levels was changed from ≥100 mg/dL to ≥70 mg/dL.

Participant flow

The study was conducted at 8 centers in 4 countries. A total of 204 participants were screened between July 2012 and November 2012, 101 of whom were screen failures. Screen failures were mainly due to exclusion criteria met.

Participant flow — Overall Study
MilestoneEzetimibe 10 mgAlirocumab 75/Up to 150 mg Q2W
Started5152
Treated5152
Completed4444
Not completed78
Withdrew: Poor compliance to protocol10
Withdrew: Consent withdrawn by participant01
Withdrew: Participant moved01
Withdrew: Adverse event45
Withdrew: Site scheduling error11
Withdrew: Protocol violation10

Outcome measures

PrimaryPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis

Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis
percent changeEzetimibe 10 mgAlirocumab 75/Up to 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis-15.6 ± 3.1-47.2 ± 3.0
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -31.6 · 95% CI -40.2 to -23.0Alirocumab vs Ezetimibe
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75/Up to 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis-19.6 ± 2.6-48.1 ± 2.6
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -28.5 · 95% CI -35.7 to -21.2Alirocumab vs Ezetimibe
SecondaryPercent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75/Up to 150 mg Q2W
Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis-11.0 ± 2.4-36.7 ± 2.3
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -25.8 · 95% CI -32.3 to -19.2Alirocumab vs Ezetimibe
SecondaryPercent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75/Up to 150 mg Q2W
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis-15.1 ± 2.9-40.6 ± 2.8
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -25.5 · 95% CI -33.5 to -17.4Alirocumab vs Ezetimibe
SecondaryPercent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75/Up to 150 mg Q2W
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis-10.9 ± 2.2-29.6 ± 2.1
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -18.7 · 95% CI -24.7 to -12.7Alirocumab vs Ezetimibe
SecondaryPercent Change From Baseline in Apo B at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75/Up to 150 mg Q2W
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis-11.7 ± 2.1-37.3 ± 2.1
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -25.7 · 95% CI -31.5 to -19.8Alirocumab vs Ezetimibe
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75/Up to 150 mg Q2W
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis-16.7 ± 2.4-42.5 ± 2.3
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -25.8 · 95% CI -32.4 to -19.2Alirocumab vs Ezetimibe
SecondaryPercent Change From Baseline in Total-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75/Up to 150 mg Q2W
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis-12.0 ± 1.7-30.3 ± 1.7
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75/Up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -18.3 · 95% CI -23.1 to -13.5Alirocumab vs Ezetimibe
SecondaryPercentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis

Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis
percentage of participantsEzetimibe 10 mgAlirocumab 75/Up to 150 mg Q2W
Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis32.288.1
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75/Up to 150 mg Q2W · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.05.) · Odds ratio (or): 34.8 · 95% CI 8.7 to 139.0Alirocumab vs Ezetimibe
SecondaryPercentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

Adjusted percentages at Week 24 from multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
percentage of participantsEzetimibe 10 mgAlirocumab 75/Up to 150 mg Q2W
Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis2.459.4
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75/Up to 150 mg Q2W · Regression, Logistic · p = 0.0001 (Threshold for significance was ≤ 0.05.) · Odds ratio (or): 69.8 · 95% CI 8.8 to 556.0Alirocumab vs Ezetimibe
SecondaryPercent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75/Up to 150 mg Q2W
Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis-12.3 ± 3.8-16.7 ± 3.7
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75/Up to 150 mg Q2W · Regression, Robust · p = 0.4013 (Threshold for significance ≤ 0.05.) · Adjusted mean difference: -4.4 · 95% CI -14.8 to 5.9Alirocumab vs Ezetimibe
SecondaryPercent Change From Baseline in HDL-C at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75/Up to 150 mg Q2W
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis1.6 ± 1.96.0 ± 1.9
SecondaryPercent Change From Baseline in HDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75/Up to 150 mg Q2W
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis1.6 ± 2.09.0 ± 2.0
SecondaryPercent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75/Up to 150 mg Q2W
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis-14.2 ± 3.7-17.2 ± 3.7
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75/Up to 150 mg Q2W
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis-10.8 ± 4.3-11.9 ± 4.2
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75/Up to 150 mg Q2W
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis-2.3 ± 3.5-12.2 ± 3.4
SecondaryPercent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75/Up to 150 mg Q2W
Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis-0.6 ± 1.64.7 ± 1.6
SecondaryPercent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75/Up to 150 mg Q2W
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis-2.2 ± 1.42.3 ± 1.4

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 32 post-treatment follow-up visit) regardless of seriousness or relationship to study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezetimibe 10 mg—1/51 (2%)27/51 (52.9%)
Alirocumab 75/Up150 mg Q2W—1/52 (1.9%)25/52 (48.1%)
Most frequent serious events
Most frequent serious events
EventEzetimibe 10 mgAlirocumab 75/Up150 mg Q2W
Bone erosionMusculoskeletal and connective tissue disorders1/510/52
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/511/52
Most frequent other events
Most frequent other events
EventEzetimibe 10 mgAlirocumab 75/Up150 mg Q2W
NasopharyngitisInfections and infestations8/5112/52
InfluenzaInfections and infestations3/516/52
DiarrhoeaGastrointestinal disorders2/516/52
Upper respiratory tract infectionInfections and infestations5/512/52
Urinary tract infectionInfections and infestations3/510/52
DizzinessNervous system disorders3/511/52
NauseaGastrointestinal disorders3/513/52
Back painMusculoskeletal and connective tissue disorders3/511/52
HeadacheNervous system disorders2/513/52
ArthralgiaMusculoskeletal and connective tissue disorders2/513/52

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ezetimibe 10 mgAlirocumab 75/Up to 150 mg Q2WTotal
Mean59.6 ± 5.360.8 ± 4.660.2 ± 5.0
Sex: Female, Male
Sex: Female, Male(Participants)Ezetimibe 10 mgAlirocumab 75/Up to 150 mg Q2WTotal
Female242448
Male272855
Calculated LDL-C in mmol/L
Calculated LDL-C in mmol/L(mmol/L)Ezetimibe 10 mgAlirocumab 75/Up to 150 mg Q2WTotal
Mean3.58 ± 0.63.65 ± 0.73.62 ± 0.7
Calculated LDL-C in mg/dL
Calculated LDL-C in mg/dL(mg/dL)Ezetimibe 10 mgAlirocumab 75/Up to 150 mg Q2WTotal
Mean138.3 ± 24.5141.1 ± 27.1139.7 ± 25.8
08

Study locations

8 sites
  • Investigational Site Number 840603
    Overland Park, Kansas 66212, United States
  • Investigational Site Number 840601
    Cincinnati, Ohio 45219, United States
  • Investigational Site Number 840602
    Richmond, Virginia 23227, United States
  • Investigational Site Number 056601
    Antwerpen, 2060, Belgium
  • Investigational Site Number 246601
    Helsinki, 00290, Finland
  • Investigational Site Number 528602
    Groningen, 9711 SG, Netherlands
  • Investigational Site Number 528601
    Rotterdam, 3021 HC, Netherlands
  • Investigational Site Number 528603
    Velp, 6883 ES, Netherlands
09

References and documents

Publications

  • Roth EM, Taskinen MR, Ginsberg HN, Kastelein JJ, Colhoun HM, Robinson JG, Merlet L, Pordy R, Baccara-Dinet MT. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol. 2014 Sep;176(1):55-61. doi: 10.1016/j.ijcard.2014.06.049. Epub 2014 Jul 2. PubMed 25037695 ↗
  • Roth EM, McKenney JM. ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. Future Cardiol. 2015;11(1):27-37. doi: 10.2217/fca.14.82. PubMed 25606700 ↗
  • Mahmood T, Minnier J, Ito MK, Li QH, Koren A, Kam IW, Fazio S, Shapiro MD. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. Eur J Prev Cardiol. 2021 Jul 23;28(8):816-822. doi: 10.1177/2047487320915803. Epub 2020 Apr 10. PubMed 34298554 ↗
  • Leiter LA, Tinahones FJ, Karalis DG, Bujas-Bobanovic M, Letierce A, Mandel J, Samuel R, Jones PH. Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabet Med. 2018 Dec;35(12):1742-1751. doi: 10.1111/dme.13817. Epub 2018 Oct 9. PubMed 30183102 ↗
  • Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P, Eckel RH, Cannon CP. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016 Dec 13;134(24):1931-1943. doi: 10.1161/CIRCULATIONAHA.116.024604. Epub 2016 Oct 24. PubMed 27777279 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 2 years 4 months after primary completion. A results delay was requested in Jul 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2012
First posted
Jul 19, 2012
Start
Jul 2012
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Results delay requested
Jul 7, 2014
Results first posted
Nov 6, 2015
Last update
Nov 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01644474
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jul 19, 2012
Start date
Jul 2012
Primary completion
Jul 2013
Completion
Jul 2013
Results posted
Nov 6, 2015
Last update
Nov 6, 2015

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion